All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
43 matching companies
EXUMA’s GCAR platform combines CD3-targeted lentiviral delivery with FITNESS DRIVER for in vivo CAR engineering. Its separate rPOC SC platform incubates PBMCs with vector outside the body and should not be described as fully in vivo manufacturing. Current GCAR clinical stage was not verified.
TPST-4003 combines CD7-targeted mRNA/LNP delivery with a CD19/BCMA CAR; first IIT dosing was projected for Q4 2026, not verified as completed. Tempest separately obtained an option to license Senlang’s clinical lentiviral platform. TPST-2003 clinical results concern ex vivo CAR-T.
Senlang’s CD7-targeted lentiviral in vivo CAR-T portfolio includes a BCMA/GPRC5D candidate in Phase 1 dose escalation for relapsed/refractory myeloma. Partner Tempest disclosed an exclusive option in September 2026; an option is not an exercised license or acquisition.
Vyriad develops targeted viral genetic medicines and oncolytic therapies. Its BCMA-directed in vivo CAR-T candidate VV169 uses a retargeted lentiviral vector to engineer T cells inside the body. On September 10, 2026, the company announced that its Phase 1 study in relapsed/refractory multiple myeloma was open for enrollment at Mayo Clinic following FDA IND clearance. Patient dosing and clinical benefit were not established in that announcement.
CPTx develops single-stranded DNA payloads with nonviral LNP delivery for in vivo CAR-T. The company reports small-animal validation; durability, redosing, and immune-silence statements remain company claims. CPTx is a distinct company from Capstan and the CPTX2309 drug code.
LB2501 is a CD19/CD20 in vivo CAR-T candidate using the TaVec lentiviral platform, with an ongoing China Phase 1 study (NCT07002112). Its October 2026 U.S. IND clearance supports a planned Phase 1/2 study. Neither IND clearance nor early responses constitute approval.
Founded in 2019, the company develops mRNA, self-replicating RNA, and delivery platforms. In 2026 it reported early JCXH-213 results in two patients with ITP; these findings should be distinguished from formal registered-trial phases and independent validation.
GRIT disclosed T-cell-targeted mRNA/LNP GT801 and a separate lentiviral direction. GT801 is also developed through spinout Vivacta Bio; the two company profiles describe a shared program lineage, not two independent drugs. GRIT’s TIL clinical stages are separate.
Immunofoco’s iMagic platform uses a fusogen and T-cell-targeting modules for in vivo CAR-T. It identifies CD19 IMV101 in IITs, alongside BCMA IMV102 and CLDN18.2 IMV103. Phase 3 IMC002 is an ex vivo program and does not establish in vivo Phase 3 development.
EVM18 delivers CD19 CAR mRNA in targeted LNPs. Everest’s 2026 interim results report IIT initiation in autoimmune disease and global IND preparation. EVM14 and EVM16 are cancer vaccines, not its in vivo CAR-T lead.
Stylus combines engineered recombinases with cell-targeted LNP delivery to create durable in vivo CAR-T through sequence-specific insertion. Its platform disclosure establishes preclinical research intent and mechanism, not patient benefit or demonstrated clinical safety.
Manufacturing partner uBriGene identifies Cellinfinity’s CIB-301 and CIB-350 as in vivo CAR-T programs for hematologic and solid tumors, supported by lentiviral vector manufacturing. The March 2026 announcement does not establish a registered clinical phase or human efficacy.
Thesian’s ARIANE platform uses in vivo engineering to generate CAR-T and CAR-macrophages for oncology and autoimmune disease. The company describes lentiviral engineering expertise and a dual-lineage approach. A named clinical-stage candidate and patient efficacy were not verified.
GigaMune develops diverse viral pseudotypes for repeat-dose in vivo CAR-T delivery and shows anti-CD19 mouse proof of concept. Proposed sequential dosing and immune evasion are platform hypotheses; human redosing safety and efficacy have not been established.
Immugenia discloses lentiviral in vivo CAR delivery to T/NK cells and HSCs, with promoter-restricted expression in T/NK lineages. HSC-derived replenishment differs from direct mature-T-cell engineering. The public disclosure does not establish a current CAR-T clinical phase.
uBriGene provides lentiviral process development, GMP manufacturing, and regulatory support for Cellinfinity’s in vivo CAR-T programs. Its manufacturing partnership establishes an enabling role; it does not establish ownership of the therapeutic candidates.
Offers data science-assisted biologics formulation, lyophilization, and viral vector formulation services. Small-scale non-GMP production and commercial GMP manufacturing require separate confirmation.
Biodextris offers Vaccine and biologics analytical development, validation and quality testing. This is the analytical service business of an integrated CRO/CDMO.
IQVIA Laboratories（含原Nexelis） offers PK, immunogenicity, vaccine assays and biomarkers; includes legacy Nexelis. Services should be matched to the intended study and assay requirements.
Coverage expands from sourced records; this database does not claim all biopharma companies.
